The first publically available results from clinical trials using p110δ inhibitors suggest a remarkable response rate in patients with chronic lymphocytic leukemia, nearly all of whom showed reduced lymph node size after treatments in phase I trials (Furman et al., 2010). The gene discussed is PIK3CD; the disease is B-cell chronic lymphocytic leukemia.